ANDA 76309, held by Dr Reddys Labs Inc. Nefazodone Hydrochloride.
As of Nov 16, 2026, ANDA 76309 (Nefazodone Hydrochloride), held by Dr Reddys Labs Inc, was first approved by FDA on Sep 16, 2003, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 16, 2003 | Original application | Approved | None posted |
| Nefazodone Hydrochloride50MG · tablet;oral | Nefazodone Hydrochloride | Discontinued |
| Nefazodone Hydrochloride100MG · tablet;oral | Nefazodone Hydrochloride | Discontinued |
| Nefazodone Hydrochloride150MG · tablet;oral | Nefazodone Hydrochloride | Discontinued |
| Nefazodone Hydrochloride200MG · tablet;oral | Nefazodone Hydrochloride | Discontinued |
| Nefazodone Hydrochloride250MG · tablet;oral | Nefazodone Hydrochloride | Discontinued |
| Jun 24, 2025 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jul 18, 2014 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jan 31, 2006 | Supplement 3Labeling | Approved | None posted |
| May 17, 2005 | Supplement 2Labeling | Approved | None posted |
| May 17, 2005 | Supplement 1Labeling | Approved | None posted |
| Sep 16, 2003 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters